Treatment of Resectable Gallbladder Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 25

PMID 35326566

Authors

Eduardo A Vega

Sebastian Mellado

Omid Salehi

Richard Freeman

Claudius Conrad

Affiliations

Soon will be listed here.

Abstract

Gallbladder cancer (GBC) is the most common biliary tract cancer worldwide and its incidence has significant geographic variation. A unique combination of predisposing factors includes genetic predisposition, geographic distribution, female gender, chronic inflammation, and congenital developmental abnormalities. Today, incidental GBC is the most common presentation of resectable gallbladder cancer, and surgery (minimally invasive or open) remains the only curative treatment available. Encouragingly, there is an important emerging role for systemic treatment for patients who have R1 resection or present with stage III-IV. In this article, we describe the pathogenesis, surgical and systemic treatment, and prognosis.

Citing Articles

Dynamic gene expression pattern in zebrafish gallbladder: an experimental study.

Tanwar P, Bhattacharya D, Dasari A, Bijwe M, Rana R, Gupta I Int J Surg. 2024; 110(12):7585-7589.

PMID: 39621022 PMC: 11634144. DOI: 10.1097/JS9.0000000000002135.

A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer.

Ozturk N, Dadamyan A, Jamil L Healthcare (Basel). 2024; 12(20).

PMID: 39451505 PMC: 11507044. DOI: 10.3390/healthcare12202091.

Novel multifactor predictive model for postoperative survival in gallbladder cancer: a multi-center study.

Deng K, Xing J, Xu G, Ma R, Jin B, Leng Z World J Surg Oncol. 2024; 22(1):263.

PMID: 39354502 PMC: 11445856. DOI: 10.1186/s12957-024-03533-z.

A prognostic model and novel risk classification system for radical gallbladder cancer surgery: A population-based study and external validation.

Feng Y, Yang J, Wang A, Liu X, Peng Y, Cai Y Heliyon. 2024; 10(15):e35551.

PMID: 39170241 PMC: 11336743. DOI: 10.1016/j.heliyon.2024.e35551.

Parthenolide induces gallbladder cancer cell apoptosis via MAPK signalling.

Obulkasim H, Aji G, Abudoula A, Liu Y, Duan S Ann Med Surg (Lond). 2024; 86(4):1956-1966.

PMID: 38576937 PMC: 10990370. DOI: 10.1097/MS9.0000000000001828.

References

Kuipers H, de Bitter T, de Boer M, van der Post R, Nijkamp M, de Reuver P . Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. Cancers (Basel). 2021; 13(21). PMC: 8582530. DOI: 10.3390/cancers13215257. View

Li Y, Zhang J, Ma H . Chronic inflammation and gallbladder cancer. Cancer Lett. 2013; 345(2):242-8. DOI: 10.1016/j.canlet.2013.08.034. View

Javle M, Borad M, Azad N, Kurzrock R, Abou-Alfa G, George B . Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021; 22(9):1290-1300. DOI: 10.1016/S1470-2045(21)00336-3. View

Duarte I, Llanos O, DOMKE H, Harz C, Valdivieso V . Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples. Cancer. 1993; 72(6):1878-84. DOI: 10.1002/1097-0142(19930915)72:6<1878::aid-cncr2820720615>3.0.co;2-2. View

Jeong H, Jeong J, Kim K, Lee S, Oh D, Park D . Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. Cancers (Basel). 2021; 13(2). PMC: 7825072. DOI: 10.3390/cancers13020161. View

Cziupka K, Partecke L, Mirow L, Heidecke C, Emde C, Hoffmann W . Outcomes and prognostic factors in gallbladder cancer: a single-centre experience. Langenbecks Arch Surg. 2012; 397(6):899-907. DOI: 10.1007/s00423-012-0950-8. View

Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M . Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res. 2014; 7(2):42-8. PMC: 4007675. View

Duffy A, Capanu M, Abou-Alfa G, Huitzil D, Jarnagin W, Fong Y . Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008; 98(7):485-9. DOI: 10.1002/jso.21141. View

Smyth M, Dunn G, Schreiber R . Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006; 90:1-50. DOI: 10.1016/S0065-2776(06)90001-7. View

10.

de Aretxabala X, Leon J, Hepp J, Maluenda F, Roa I . Gallbladder cancer: role of laparoscopy in the management of potentially resectable tumors. Surg Endosc. 2010; 24(9):2192-6. DOI: 10.1007/s00464-010-0925-1. View

11.

Ben-Josef E, Guthrie K, El-Khoueiry A, Corless C, Zalupski M, Lowy A . SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015; 33(24):2617-22. PMC: 4534524. DOI: 10.1200/JCO.2014.60.2219. View

12.

Weiland S, Mahvi D, Niederhuber J, Heisey D, Chicks D, Rikkers L . Should suspected early gallbladder cancer be treated laparoscopically?. J Gastrointest Surg. 2002; 6(1):50-6; discussion 56-7. DOI: 10.1016/s1091-255x(01)00014-2. View

13.

Serra I, Calvo A, Maturana M, Medina E, Sharp A . Changing trends of gall-bladder cancer in Chile, a high-risk area. Int J Cancer. 1990; 45(2):376-7. DOI: 10.1002/ijc.2910450228. View

14.

Lin J, Peng X, Dong K, Long J, Guo X, Li H . Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nat Commun. 2021; 12(1):4753. PMC: 8346570. DOI: 10.1038/s41467-021-25012-9. View

15.

Fong Y, Jarnagin W, Blumgart L . Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000; 232(4):557-69. PMC: 1421188. DOI: 10.1097/00000658-200010000-00011. View

16.

Machado M, Makdissi F, Surjan R . Totally Laparoscopic Hepatic Bisegmentectomy (s4b+s5) and Hilar Lymphadenectomy for Incidental Gallbladder Cancer. Ann Surg Oncol. 2015; 22 Suppl 3:S336-9. DOI: 10.1245/s10434-015-4650-9. View

17.

Yamashita S, Loyer E, Chun Y, Javle M, Lee J, Vauthey J . Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. Ann Surg Oncol. 2016; 23(Suppl 5):892-893. DOI: 10.1245/s10434-016-5436-4. View

18.

Wistuba I, Gazdar A . Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004; 4(9):695-706. DOI: 10.1038/nrc1429. View

19.

Vega E, Sanhueza M, Vinuela E . Minimally Invasive Surgery for Gallbladder Cancer. Surg Oncol Clin N Am. 2019; 28(2):243-253. DOI: 10.1016/j.soc.2018.11.001. View

20.

Butte J, Gonen M, Allen P, DAngelica M, Kingham T, Fong Y . The role of laparoscopic staging in patients with incidental gallbladder cancer. HPB (Oxford). 2011; 13(7):463-72. PMC: 3133713. DOI: 10.1111/j.1477-2574.2011.00325.x. View